Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Kelly Dooley

Mycobacterial Disease · Vanderbilt

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

    Feb 17, 2024DOI: 10.1093/cid/ciad576Journal ArticleCID

    Written by: Jessica Howard-AndersonToshimitsu HamasakiWeixiao DaiDeborah CollyarDaniel RubinSumathi NambiarTori KinamonHeidi Leister-TebbeCarol HillHolly GeresThomas L HollandSarah B DoernbergHenry F ChambersVance G FowlerScott R EvansHelen W BoucherAntibacterial Resistance Leadership Group

    Find these authors on Roon

    HB
    Dr. Helen Boucher
    Transplant/Immunocompromised States · Tufts

    Summary

    BACKGROUND: Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are frequently caused by multidrug-resistant organisms. Patient-centered endpoints in clinical trials are needed to develop new antibiotics for HABP/VABP. Desirability of outcome ranking (DOOR) is a paradigm for the design, analysis, and interpretation of clinical trials based on a patient-centered, benefit-risk evaluation.METHODS: A multidisciplinary committee created an infectious diseases DOOR endpoint customized for HABP/VABP, incorporating infectious complications, serious adverse events, and mortality. We applied this to 2 previously completed, large randomized controlled trials for HABP/VABP. ZEPHyR compared vancomycin to linezolid and VITAL compared linezolid to tedizolid. For each trial, we evaluated the DOOR distribution and probability, including DOOR component and partial credit analyses. We also applied DOOR in subgroup analyses.RESULTS: In both trials, the HABP/VABP DOOR demonstrated similar overall clinical outcomes between treatment groups. In ZEPHyR, the probability that a participant treated with linezolid would have a more desirable outcome than a participant treated with vancomycin was 50.2% (95% confidence interval [CI], 45.1%--55.3%). In VITAL, the probability that a participant treated with tedizolid would have a more desirable outcome than a participant treated with linezolid was 48.7% (95% CI, 44.8%-52.6%). The DOOR component analysis revealed that participants treated with tedizolid had a less desirable outcome than those treated with linezolid when considering clinical response alone. However, participants with decreased renal function had improved overall outcomes with tedizolid.CONCLUSIONS: The HABP/VABP DOOR provided more granular information about clinical outcomes than is typically presented in clinical trials. HABP/VABP trials would benefit from prospectively using DOOR.
    HBDr. Helen Boucher
    Leading Voice

    Dr. Helen Boucher

    Infectious Disease · Transplant/Immunocompromised States
    Tufts University
    helen